250 related articles for article (PubMed ID: 25600792)
41. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
[TBL] [Abstract][Full Text] [Related]
42. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
43. Clinical histopathological features and CDKN2A/CDK4/MITF mutational status of patients with multiple primary melanomas from Bologna: Italy is a fascinating but complex mosaic.
Dika E; Patrizi A; Rossi C; Turchetti D; Miccoli S; Ferracin M; Veronesi G; Scarfì F; Lambertini M
Ital J Dermatol Venerol; 2021 Oct; 156(5):599-605. PubMed ID: 32221274
[TBL] [Abstract][Full Text] [Related]
44. Genetic mutations involved in melanoma: a summary of our current understanding.
High WA; Robinson WA
Adv Dermatol; 2007; 23():61-79. PubMed ID: 18159896
[TBL] [Abstract][Full Text] [Related]
45. Genetics of familial melanoma: 20 years after CDKN2A.
Aoude LG; Wadt KA; Pritchard AL; Hayward NK
Pigment Cell Melanoma Res; 2015 Mar; 28(2):148-60. PubMed ID: 25431349
[TBL] [Abstract][Full Text] [Related]
46. The interplay of sun damage and genetic risk in Australian multiple and single primary melanoma cases and controls.
McMeniman EK; Duffy DL; Jagirdar K; Lee KJ; Peach E; McInerney-Leo AM; De'Ambrosis B; Rayner JE; Smithers BM; Soyer HP; Sturm RA
Br J Dermatol; 2020 Aug; 183(2):357-366. PubMed ID: 31794051
[TBL] [Abstract][Full Text] [Related]
47. Clinical applications of melanoma genetics.
Gabree M; Patel D; Rodgers L
Curr Treat Options Oncol; 2014 Jun; 15(2):336-50. PubMed ID: 24652319
[TBL] [Abstract][Full Text] [Related]
48. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
[TBL] [Abstract][Full Text] [Related]
49. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
[TBL] [Abstract][Full Text] [Related]
50. 3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.
Tovar-Parra D; Gil-Quiñones SR; Nova J; Gutiérrez-Castañeda LD
In Vivo; 2021; 35(3):1529-1536. PubMed ID: 33910831
[TBL] [Abstract][Full Text] [Related]
51. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.
Fargnoli MC; Gandini S; Peris K; Maisonneuve P; Raimondi S
Eur J Cancer; 2010 May; 46(8):1413-20. PubMed ID: 20189796
[TBL] [Abstract][Full Text] [Related]
52. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.
Star P; Goodwin A; Kapoor R; Conway RM; Long GV; Scolyer RA; Guitera P
Eur J Cancer; 2018 Mar; 92():48-53. PubMed ID: 29413689
[TBL] [Abstract][Full Text] [Related]
53. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
54. Genetic variations of patients with familial or multiple melanoma in Southern Brazil.
Grazziotin TC; Rey MC; Bica CG; Pinto LA; Bonamigo RR; Puig-Butille JA; Cuellar F; Puig S
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e179-85. PubMed ID: 22621339
[TBL] [Abstract][Full Text] [Related]
55. Genetics: what advice for patients who present with a family history of melanoma?
Newton Bishop JA; Gruis NA
Semin Oncol; 2007 Dec; 34(6):452-9. PubMed ID: 18083368
[TBL] [Abstract][Full Text] [Related]
56. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
57. [Genotypic hypervariability of melanoma: a therapeutic challenge].
Dalle S; Martin-Denavit T; Thomas L
Med Sci (Paris); 2006 Feb; 22(2):178-82. PubMed ID: 16457759
[TBL] [Abstract][Full Text] [Related]
58. Melanoma susceptibility genes and risk assessment.
Marzuka-Alcalá A; Gabree MJ; Tsao H
Methods Mol Biol; 2014; 1102():381-93. PubMed ID: 24258989
[TBL] [Abstract][Full Text] [Related]
59. Molecular genetics of familial cutaneous melanoma.
Haluska FG; Hodi FS
J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
[TBL] [Abstract][Full Text] [Related]
60. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
